Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Notes Payables (2016 - 2019)

Lineage Cell Therapeutics (LCTX) has 5 years of Notes Payables data on record, last reported at $18000.0 in Q1 2019.

  • For Q1 2019, Notes Payables fell 85.0% year-over-year to $18000.0; the TTM value through Mar 2019 reached $18000.0, down 85.0%, while the annual FY2018 figure was $70000.0, 53.95% down from the prior year.
  • Notes Payables reached $18000.0 in Q1 2019 per LCTX's latest filing, down from $70000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $1.1 million in Q1 2017 and bottomed at $13000.0 in Q3 2017.
  • Average Notes Payables over 5 years is $182400.0, with a median of $99000.0 recorded in 2016.
  • The widest YoY moves for Notes Payables: up 1026.32% in 2017, down 96.36% in 2017.
  • A 5-year view of Notes Payables shows it stood at $95000.0 in 2015, then increased by 4.21% to $99000.0 in 2016, then skyrocketed by 53.54% to $152000.0 in 2017, then plummeted by 53.95% to $70000.0 in 2018, then plummeted by 74.29% to $18000.0 in 2019.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $18000.0 in Q1 2019, $70000.0 in Q4 2018, and $70000.0 in Q3 2018.